Background We identified a mitochondrial tRNA mutation (m.586 G>A) in a patient with renal failure and symptoms consistent with a mitochondrial cytopathy. This mutation was of unclear significance due to the absence of consistent reports of linkage to specific disease phenotypes and any data pertaining to its effects on mitochondrial function.
Introduction
We report a case of a child who presented with multi-organ dysfunction, including severe neurologic and renal impairment, who ultimately succumbed due to neurological deterioration while on peritoneal dialysis. Mitochondrial cytopathies are an uncommon cause of renal failure [1] , but in our patient the diagnosis was suggested by the combination of clinical features.
Mitochondrial DNA (mtDNA) sequencing led to the identification of an m.586 G>A mutation affecting the mitochondrial tRNA for phenylalanine (MTTF). This mutation had been previously reported in a 57-year-old woman with movement disorder and psychiatric disease [2] . In the previous case the mutation was heteroplasmic with loads of 85 % in muscle, 29 % in urinary epithelia, and 3 % in blood. The authors showed that COX-negative fibers from this patient had a disproportionate load of the mutation and concluded that it was pathogenic. The disparity in severity, onset, and affected tissues prompted us to consider whether m.586 G>A was responsible for mitochondrial dysfunction or was merely coincidental.
It is often difficult to conclusively link mitochondrial mutations to the mechanism of disease. The evaluation of mitochondrial function in patient tissues is dependent upon biopsy and analytical techniques. The presence of variable heteroplasmic loads of the mutation in ostensibly healthy family members complicates the interpretation of genetic testing. To confirm the pathogenicity of the m.586 G>A mutation, we examined the effect of the mutation on oxygen consumption, mitochondrial protein levels, and tRNA Phe levels in patient tissues and in transmitochondrial cybrid cell lines.
Patient and methods

Case report
The proband was aged 16 months at the time of evaluation. At 8 months she had failure-to-thrive, microcephaly, hypotonia, and gastroparesis. Symptoms progressed to include developmental regression, adrenal insufficiency, pancreatitis, anemia, and neutropenia. At 15 months she was admitted for feeding intolerance and hyponatremia. Maintenance medications upon admission included hydrocortisone, clonidine, and erythropoietin. She had proteinuria (urine albumin 288 mg/L), hypertension, and enlarged, echogenic kidneys on the ultrasound scan. A renal biopsy showed chronic tubulointerstitial fibrosis, and electron microscopy examination revealed dilated mitochondria without distortion of the cristae. Despite aggressive management she remained hypertensive and volume overloaded, with the serum urea concentration increasing to 101 mg/dL (normal range 2-19 mg/dL) and the serum creatinine concentration increasing to 1.2 mg/dL (normal range 0.1-0.4 mg/dL). The development of pleural effusions and pulmonary edema necessitated continuous veno-venous hemodiafiltration. She transitioned to peritoneal dialysis, which continued until her death at 24 months.
Laboratory analysis included elevated lactate (5.62-8.95 mM; normal 0.8-2 mM) and pyruvate (0.18-0.23 mM; normal 0.05-0.14 mM) levels. Serial brain magnetic resonance imaging (MRI) revealed progressive volume loss with white matter changes in the periventricular and centrum semiovale white matter, bilateral hippocampi, and putamina. MR spectroscopy revealed a lactate doublet within the basal ganglia, the centrum semiovale, and the ventricles. The results of the clinical laboratory evaluation of the electron transport chain in muscle were normal. The TrnF mutation (m.586 G>A) was identified clinically using Sanger sequencing of the muscle and blood. This mutation was not identified in her mother. A rare homoplasmic polymorphism, m.5746 G>A, was identified in the proband and her mother.
Cell culture
Fibroblasts were obtained by skin biopsy and cultured in DMEM (Gibco, Invitrogen, Carlsbad, CA) supplemented with 10 % fetal calf serum, pyruvate (110 μg/mL) and uridine (500 μg/mL). Cybrids were created from patient fibroblasts and 143B ρ 0 osteosarcoma cells (a gift from Michael King) using previously described protocols [3] .
Detection of mitochondrial heteroplasmy
The mitochondrial sequence from nt.467-828 was amplified and sequenced with forward primer CCCATACTAC TAATCTCATCA and reverse primer GTTAATCACTGCT GTTTCCCG.
Oxygen consumption studies Cybrid lines were assayed for oxygen consumption using an XF24 (Seahorse Biosciences, North Billerica, MA) as previously described [4] . Cells were plated at 30,000 cells per well and sequentially treated with oligomycin (1 μM), dinitrophenol (150 μM) and rotenone (160nM). Samples were analyzed in quadruplicate and the values normalized to protein concentration.
Northern blotting RNA samples were produced from nearly confluent fibroblast cultures using Trizol (Invitrogen) and resolved on a 15 % acrylamide/TBE gel before being transferred to a Hybond N+ membrane (GE-Amersham, Little Chalfont, UK). Mitochondrial tRNAs were identified by Northern blotting [4] . The probe for tRNA Phe hybridizes to positions encoded by nucleotides 594-613 to avoid interference from the m.586 G>A mutation.
Western blotting
Whole cell protein extracts from cybrid cells were evaluated with the following antibodies: complex I subunit NDUFA9 (MS111; MitoSciences, Eugene, OR), complex II subunit 70 kDa (MS204; MitoSciences), complex III subunit core 2 (MS304; MitoSciences), and ATP synthase subunit alpha (MS507; MitoSciences). Actin ( sc-1616; Santa Cruz Biotechnology; Santa Cruz, CA) was used as a loading control. Western blots were imaged with a chemiluminescent detection system (VersaDoc) as previously described [4] .
Results
Patient and cybrid heteroplasmy
Resequencing of the DNA derived from the proband's fibroblasts confirmed the m.586 G>A mutation. Low levels of the wild-type allele were also detected, suggesting that the mutation was heteroplasmic (data not shown). To study the mutation in isolation, we created mitochondrial cybrid lines from the fusion of patient's fibroblasts and 143Bρ 0 cells. Three distinct lines were isolated: a wild-type m.586 G cybrid, a heteroplasmic cybrid with approximately 70 % mutant load, and a homoplasmic mutant m.586A cybrid. All of the tested lines were homoplasmic for the m.5746 G>A variant that was identified in both the patient and her mother. This polymorphism has been previously identified in a database of normal human mtDNA variation [5] .
Oxygen consumption in cybrid cells
Oxygen consumption was evaluated in intact cybrid cells. Basal respiration was severely reduced in the homoplasmic mutant m.586 G>A cell line, and there was a trend towards decreasing respiration in the heteroplasmic line when compared to the wild-type cybrid (Fig. 1a) . The addition of oligomycin, which inhibits the F 0 F 1 -ATPase, had a similar effect upon the heteroplasmic and wild-type cybrid lines. Maximal respiration induced by the addition of the uncoupler dinitrophenol was again somewhat lower in the heteroplasmic cybrid line compared with the homoplasmic wild-type cybrids. The homoplasmic mutant cybrid had very reduced oxygen uptake under all tested conditions. tRNA and protein levels in cybrids Since the m.586 G>A mutation may destabilize the tRNA, we investigated the levels of MTTF by Northern blotting. There was a significant reduction of MTTF in patient fibroblasts compared to an unaffected control, with increased expression of the other tRNAs tested (Fig. 1b) . Similarly, Northern blotting of the three cybrid lines showed a dosedependent decrease of MTTF in the heteroplasmic and mutant cybrids (Fig. 1c) . The levels of other mitochondrial tRNAs were unaffected or even increased in the m.586 G> A cybrid.
Western blotting of mitochondrial extracts from all three cybrid lines was performed to look at the effect of the mutation on the electron transport chain subunits (Fig. 1d) . The homoplasmic mutant cybrid line had reduced levels of complex I and III subunits, as compared to the wild-type and heteroplasmic cybrids.
Oxygen Consumption (pmol/min/mg protein) G>A (circles), heteroplasmic (triangles), or homoplasmic wild-type (squares) were analyzed, along with parental strain 143Bρ 0 (diamonds). Oligomycin, dinitrophenol, and rotenone were added at the times indicated. The m.568 G>A strain showed significantly diminished oxygen consumption under both basal and dinitrophenol (DNP)-stimulated conditions (10 and 5 %, respectively; p< 0.01, t-test). Bars Standard error (a). Levels of mitochondrial tRNAs were analyzed by Northern blotting. Total RNA was extracted from proband fibroblasts (b) and cybrid lines (c), resolved on acrylamide gels, and blotted with probes for the mitochondrial tRNAs for phenylalanine, glutamine, threonine, and valine. Western blotting for subunits of the electron transport chain in cybrid whole cell extracts (d). Mut Mutant, WT wild type
Discussion
We have studied the m.586 G>A mutation which has now been observed in two unrelated probands. At the time of evaluation, our patient was a 16-month-old girl with chronic kidney disease, lactic acidosis, developmental delay, and multi-organ involvement. The previously reported patient with this mutation was a 57-year-old woman with psychiatric problems, dementia, and akinesia-rigidity [2] . Despite the differences in these presentations, we have confirmed that m.586 G>A is pathogenic and not a neutral polymorphism. Basal and maximally stimulated oxygen consumption in cybrids harboring the mutation is impaired in a dosedependent manner. Levels of the tRNA Phe were significantly reduced in both the patient and in cybrid lines bearing the m.586 G>A mutation. Cybrids carrying the m.586 G>A mutation had reduced levels of electron transport chain subunits, likely due to the mutation's deleterious effects on translation and the subsequent turnover of incompletely formed complexes.
Renal involvement is observed in several mitochondrial disorders, such as the Pearson, Leigh, and Kearns-Sayre syndromes (for more complete reviews see [6, 7] ). The common MELAS mutation m.3243A>G has been implicated in steroid-resistant focal segmental glomerulosclerosis [8] , an Alport syndrome-like phenotype [9] , maternally inherited diabetes, and deafness [10] and in a patient with renal cancer and nephrotic syndrome [11] . Patients with both isolated and syndromic renal disease have been found to have other, novel mtDNA mutations, such as a 7.3-kb mtDNA deletion in a patient with renal Fanconi syndrome [12] and a frame-shift deletion of m.12425delA in a patient with complex I deficiency, renal failure, and myopathy [13] . Here, we add a new mtDNA mutation, m.586 G> A, to the list of mitochondrial DNA mutations associated with renal disease and as a cause of chronic tubulointerstitial nephritis.
Based on the clinical history of the proband, the evolutionary conservation of the base-pair created by m.586 G> A, and cybrid studies, the mutation scores as definitely pathogenic using a scale for determining the impact of mitochondrial tRNA variation [14] . In light of our patient's phenotype, the absence of renal pathology in the m.586A> G-affected patient described by Young and colleagues is intriguing [2] . One possibility is that the low levels of m.586A>G in urine-derived DNA, presumably from the renal epithelium, reflect a lower level of heteroplasmy in the kidneys, with subsequent organ-specific escape from mitochondrial injury.
In summary we describe a child with a novel mitochondrial mutation causing tubulointerstitial fibrosis and neurological deterioration that was progressive. The phenotype of this tRNA Phe mitochondrial mutation should be added to the multiple ways in which kidney disease can manifest in children with mitochondrial disorders.
